Poznan

• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Recruiting
  2024-518296-56-00 5 2025-09-29 Crohn’s Disease
• A Phase 3 Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder Recruiting
  2024-520259-26-00 5 2025-09-25 Mania or Mania with Mixed Features in Bipolar-I Disorder
• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obe … Recruiting
  2024-520209-38-00 5 2025-09-19 Obesity or Overweight
• A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Monotherapy Study of the Efficacy, Safety, and Tolerability of SPT-300 in Ad … Recruiting
  2025-521240-37-00 4 2025-09-11 Major Depressive Disorder (MDD), with or without Anxious Distress
• Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR) Recruiting
  2024-520107-12-00 5 2025-09-03 Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo
• A clinical study of treatments for non-small cell lung cancer (MK-3475-01I) Recruiting
  2024-518839-11-00 4 2025-08-25 Stage IV Squamous Non-Small Cell Lung Cancer
• A randomized, placebo-controlled trial to evaluate the safety and efficacy of Debio 4126 in patients with acromegaly previously treated with … Recruiting
  2024-516616-24-00 5 2025-07-23 Acromegaly
• A phase 2 placebo-controlled trial to investigate visugromab in combination with immunochemotherapy (ICT) in first-line treatment of partici … Recruiting
  2024-516792-32-01 4 2025-07-18 Metastatic non-squamous non-small cell lung cancer
• A Study to Learn About the Study Medicine Called Sigvotatug Vedotin in People with Locally Advanced, Unresectable, or Metastatic Non-Small C … Recruiting
  2024-517968-36-00 5 2025-07-08 non-small cell lung cancer
• A phase 1 trial to evaluate the safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of VIS171 in participants with … Recruiting
  2024-518976-30-00 3 2025-07-02 Systemic lupus erythematosus
• A phase 2/3, multi-center, study of L-Annamycin in combination with cytarabine vs. placebo in combination with cytarabine as second line the … Recruiting
  2024-518359-47-00 10 2025-06-17 Acute Myeloid Leukemia
• A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with … Recruiting
  2024-513965-38-01 5 2025-06-16 Sjögren's Disease
• A Phase I, Open-Label Study of CLN-978 in Patients with Treatment-Refractory Rheumatoid Arthritis (RA) Recruiting
  2024-519114-31-00 3 2025-05-15 Treatment-Refractory Rheumatoid Arthritis
• A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Pso … Recruiting
  2024-515706-77-00 5 2025-05-08 Moderate to Severe Plaque Psoriasis
• A Study to see How Well and How Safely Different Treatments Work in a Group of Patients with Non-Small Cell Lung Cancer, Chosen Based on the … Recruiting
  2024-511239-91-00 4 2025-05-05 Resectable Stage I-III Non-Small Cell Lung Cancer (NSCLC)
• A Phase 2 Study of AMG 193 in Subjects With MTAP-deleted Advanced NSCLC Recruiting
  2024-514459-14-00 4 2025-04-22 Non-Small Cell Lung Cancer
• A Study to Assess the Effectiveness and Safety of Induction Therapy with RO7790121 in Participants with Moderately to Severely Active Crohn' … Recruiting
  2024-513054-30-00 5 2025-04-16 Moderately to Severely Active Crohn's Disease (CD)
• A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-022) Recruiting
  2023-508015-23-00 5 2025-04-11 Ovarian cancer recurrent
• A Randomized, Double-Blind, Placebo-Controlled, MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemal … Recruiting
  2023-507097-41-01 5 2025-03-20 Patients with limited-stage small cell lung cancer (LS-SCLC) without
• A Phase 3 Double-blind Study to Evaluate the Efficacy and Safety of Oral Ozanimod Compared to Oral Fingolimod in Children and Adolescents wi … Recruiting
  2022-501332-42-00 5 2025-02-26 Relapsing Remitting Multiple Sclerosis
• An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients w … Recruiting
  2023-507853-13-00 4 2025-02-25 Ulcerative Colitis
• A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis Recruiting
  2024-512126-29-00 5 2025-02-25 Generalized Myasthenia Gravis
• A study to investigate efficacy and safety of INT230-6 compared with US standard of care in participants aged ≥ 18 years old with metastatic … Recruiting
  2024-512423-36-00 5 2024-11-20 Undifferentiated pleomorphic sarcoma
• Study Evaluating Tarlatamab After Chemoradiotherapy in Limited‑Stage Small‑Cell Lung Cancer (DeLLphi-306) Recruiting
  2023-506235-15-00 5 2024-11-07 Limited-Stage Small-Cell Lung Cancer (LS SCLC)

Showing 97–120 of 914 trials